A 2025 JAMA Psychiatry clinical trial found that adults with alcohol use disorder taking weekly semaglutide experienced significant reductions in alcohol cravings and consumption compared to placebo (source)
Retatrutide is a triple agonist that includes full GLP-1 activation as part of its mechanism, plus GIP and glucagon receptor activity
Understanding your specific category matters because it shapes every subsequent conversation with providers and insurers
Together, they reduce emotional eating by targeting the brains reward system
However, these results must be contextualised carefully: Phase 2 trials are not powered to detect cardiovascular outcomes such as myocardial infarction, stroke, or cardiovascular mortality No dedicated cardiovascular outcome trial (CVOT) data exist for retatrutide such trials are required before definitive conclusions about cardiovascular benefit or risk can be drawn
Its loss reduces basal metabolic rate which is one reason GLP-1 discontinuation is associated with significant weight regain risk
.png)
